Physician profile
Robin Conley
NPI 1679094452
$2,133.79
in general payments reported to CMS, 2019-2025
28 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.04 · 2021: $12.44 · 2022: $32.27 · 2023: $16.86 · 2024: $110 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,037 · Education: $39.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.09 |
| Education | $39.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $302.06 | 2022-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $228.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $182.68 | 2024-2025 | |
| Lilly USA, LLC | $160.95 | 2022-2025 | Mounjaro, Kisunla, Jardiance |
| Abbvie INC. | $160.40 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $121.53 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $117.64 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $109.27 | 2025 | Auvelity, Symbravo |
| Amgen INC. | $73.49 | 2025 | Krystexxa, Otezla, Repatha |
| Astellas Pharma US INC | $66.89 | 2025 | Veozah |
| Dexcom, INC. | $64.31 | 2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $55.32 | 2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $55.24 | 2025 | |
| Paratek Pharmaceuticals, INC. | $53.56 | 2025 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $53.20 | 2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.14 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.54 | 2020-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.50 | 2025 | Xifaxan |
| Corium, LLC | $28.21 | 2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $25.20 | 2025 | Trintellix |
| Tris Pharma INC | $23.98 | 2025 | Dyanavel Xr |
| Abbott Laboratories | $22.12 | 2025 | Freestyle Libre 3 |
| Davol INC. | $21.51 | 2025 | Phasix Mesh |
| Merck Sharp & Dohme LLC | $19.68 | 2025 | Gardasil 9, Capvaxive |
| Corcept Therapeutics | $19.32 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $17.48 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $16.97 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $13.40 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Conley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.